Evidence map›Paper›PMID 40003993›Full record

ArticleInternational journal of molecular sciences2025

Discovery of Novel Pyridin-2-yl Urea Inhibitors Targeting ASK1 Kinase and Its Binding Mode by Absolute Protein-Ligand Binding Free Energy Calculations.

Lingzhi Wang, Yalei Gao, Yuying Chen, Zhenzhou Tang, Xiao Lin, Meng Bai, Pei Cao, Kai Liu

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lingzhi WangGuangxi Key Laboratory of Marine Drugs, Guangxi University of Chinese Medicine, Nanning 530200, China.
Yalei GaoGuangxi Key Laboratory of Marine Drugs, Guangxi University of Chinese Medicine, Nanning 530200, China.
Yuying ChenGuangxi Key Laboratory of Marine Drugs, Guangxi University of Chinese Medicine, Nanning 530200, China.
Zhenzhou TangGuangxi Key Laboratory of Marine Drugs, Guangxi University of Chinese Medicine, Nanning 530200, China.
Xiao LinGuangxi Key Laboratory of Marine Drugs, Guangxi University of Chinese Medicine, Nanning 530200, China.
Meng BaiGuangxi Key Laboratory of Marine Drugs, Guangxi University of Chinese Medicine, Nanning 530200, China.
Pei CaoGuangxi Key Laboratory of Marine Drugs, Guangxi University of Chinese Medicine, Nanning 530200, China.ORCID 0000-0002-2298-4667
Kai LiuGuangxi Key Laboratory of Marine Drugs, Guangxi University of Chinese Medicine, Nanning 530200, China.ORCID 0000-0002-0097-0723

Funding

Natural Science Foundation of Guangxi 2024JJA120026
6 · The paper itself

Abstract

Apoptosis signal-regulating kinase 1 (ASK1), a key component of the mitogen-activated protein kinase (MAPK) cascades, has been identified as a promising therapeutic target owing to its critical role in signal transduction pathways. In this study, we proposed novel pyridin-2-yl urea inhibitors exhibiting favorable physicochemical properties. The potency of these compounds was validated through in vitro protein bioassays. The inhibition (IC

Indexed as

MAP Kinase Kinase Kinase 5Protein Kinase InhibitorsUreaBinding SitesDrug DiscoveryHumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingThermodynamicsLigandsMAP3K5 protein, humanMAP Kinase Kinase Kinase 5Protein Kinase InhibitorsUreaabsolute binding free energy calculationapoptosis signal-regulating kinase 1binding mode predictionpyridin-2-yl urea inhibitors

Identifiers

PMID40003993
PMCPMC11854949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.